Design and Characterization of Periodically Conductive Woven Fabric

In this paper, a novel kind of electromagnetic (EM) functional textiles is proposed, which show high-pass characteristics as they interact with EM waves. The periodically conductive woven fabric was designed, fabricated, and measured. Specifically, by means of unit cell model building and EM simulation, the theoretical S21 (transmission coefficient) and S11 (reflection coefficient) curves were obtained. A concrete sample was fabricated through weaving process, and its transmission characteristics were measured in the microwave anechoic chamber. The measured and simulated results were highly consistent, demonstrating the validity of design process. Compared with the aluminum foil paper sample, the S21 values of fabricated sample were a little smaller, and the reason could be attributed to yarn crimp and surface roughness. The EM characteristics of fabricated sample under two different polarization modes were slightly different, which was due to the beating-up tension of weaving process. The work could offer new research ideas, and the related products have potential advantages over rigid plates on the account of textile characteristics

Interfacial Structure of Polytrimethylene Terephthalate/Polyethylene Terephthalate Bicomponent Filament

The interfacial structure and binding forces of polytrimethylene terephthalate/polyethylene terephthalate filament were investigated through the methods of Carbon-13 nuclear magnetic resonance (13C-NMR), differential scanning calorimeter (DSC), scanning electron microscopy (SEM) and optical microscopy. When two molten polymers met during the spinning process, an interface layer between the PTT and PET components formed and played an important role in binding the two components together. When the blending time was sufficient, an ester-interchange reaction took place with the generation of the copolymer. The PET recrystallisation was observed in the DSC curve under the influence of entangled PTT molecular chains. The morphology of the cross-section and side view proved that the linear boundary line was short and weaker in binding without a chemical bond and molecular diffusion. Side-by-side bi-component fiber and split-type fiber was able to be controllably spun by adjusting the spinning parameters

A novel methyl pyridinium salt for the detection of water content in organic solvents

A novel pyridinium salt,TM was synthesized from 2,6-dimethylpyridin.TM exhibits pronounced negative solvatochromism and possesses high absorption spectral sensitivities to water content changes.TM could be used to measure the water content in organic solvents such as THF,1,4-dioxane,acetone,and methanol.The detection limit was 0.04% for THF.The calibration curve for the determination of water in THF was obtained.TM exhibited high selectivity and sensitivity in the absorbance detection of water in organic solvents

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients from China, Malaysia, Thailand and Russia. Methods: Adult chemotherapy-naïve patients with confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade 0–1, ongoing androgen deprivation (serum testosterone <50 ng/dL) with prostate specific antigen (PSA) or radiographic progression were randomized to receive abiraterone acetate (1000 mg, QD) + prednisone (5 mg, BID) or placebo + prednisone (5 mg, BID), until disease progression, unacceptable toxicity or consent withdrawal. Primary endpoint was improvements in time to PSA progression (TTPP). Results: Totally, 313 patients were randomized (abiraterone: n = 157; prednisone: n = 156); and baseline characteristics were balanced. At clinical cut-off (median follow-up time: 3.9 months), 80% patients received treatment (abiraterone: n = 138, prednisone: n = 112). Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone, attaining 58% reduction in PSA progression risk (HR = 0.418; p < 0.0001). Abiraterone-treated patients had higher confirmed PSA response rate (50% vs. 21%; relative odds = 2.4; p < 0.0001) and were 5 times more likely to achieve radiographic response than prednisone-treated patients (22.9% vs. 4.8%, p = 0.0369). Median survival was not reached. Most common (≥10% abiraterone vs. prednisone-treated) adverse events: bone pain (7% vs. 14%), pain in extremity (6% vs. 12%), arthralgia (10% vs. 8%), back pain (7% vs. 11%), and hypertension (15% vs. 14%). Conclusion: Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naïve men with mCRPC, consistent with global study, thus supporting use of abiraterone in this patient population